Clinical Trials Browser

Phase 2 × Digestive System Neoplasms × Immune Checkpoint Inhibitors × Clear all

NCT05913661 2023-06-22

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Phase 2 Unknown

Gastrointestinal

Carcinoma, Digestive System Neoplasms, Cholangiocarcinoma